INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXGlobeNewsWire • 02/17/26
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi ArabiaBusiness Wire • 02/17/26
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent LymphomasBusiness Wire • 02/02/26
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder CancerThe Motley Fool • 01/26/26
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a MonthThe Motley Fool • 01/23/26
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free TherapyBusiness Wire • 01/23/26
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face LossesThe Motley Fool • 01/21/26
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA ResubmissionZacks Investment Research • 01/21/26
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder CancerBusiness Wire • 01/20/26
ImmunityBio Shares Surge on Updated Durable Lymphoma Study ResultsZacks Investment Research • 01/19/26
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over YearThe Motley Fool • 01/16/26
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/16/26
ImmunityBio shares rise on positive CAR-NK trial results in Waldenström lymphomaProactive Investors • 01/16/26
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom LymphomaBusiness Wire • 01/16/26
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCGBusiness Wire • 01/16/26